Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has announced the shortage of the immediate release formulation of amphetamine mixed salts, commonly referred to by the brand name Adderall.
The Agency is in frequent communication with all manufacturers of amphetamine mixed salts. Teva Pharmaceutical has stated that they are experiencing manufacturing delays, while others have stated that there is not sufficient supply to meet demands in the US.
Amphetamine mixed salts are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The FDA is recommending patients to consult their health care providers and consider alternative therapies, such as the extended-release version of amphetamine mixed salts, until supply is replenished.
The FDA is continuing to monitor the supply of amphetamine mixed salts and updating its Drug Shortage Webpage to provide additional information regarding a list of current manufacturers and product availability.
Reference
US Food and Drug Administration. FDA announces shortage of Adderall. News release. Accessed October 13, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-shortage-adderall
